超研股份于2025年1月22日在深交所创业板上市，公开发行总股数为6,424.9446万股，发行价格为6.70 元/股，保荐机构为中国银河（601881）证券股份有限公司，保荐代表人为张悦、王飞。 超研股份首次公开发行募集资金总额为43,047.13万元，扣除发行费用后募集资金净额38,436.32万元，该 公司募集资金净额比原计划多7,290.57万元。超研股份于2025年1月17日披露的招股说明书显示，该公司 拟募资31,145.75万元，用于"医用成像产品研发及产业化建设项目""工业无损检测系统研发项目""便携 式DR系统研发、产业化及市场建设项目""创新基地建设项目"。 中国经济网北京3月4日讯超研股份（301602）(301602.SZ)今日盘中最低报20.20元，创上市以来股价新 低。截至今日收盘，超研股份报20.30元，跌幅2.17%，总市值86.95亿元。 超研股份公开发行新股的发行费用合计4,610.81万元(不含增值税)，其中保荐及承销费用2,978.10万元。 ...

Summary of Key Points Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is utilizing raised funds to replace self-raised funds invested in its fundraising projects, following necessary approvals and regulations [1][5][7]. Group 1: Fundraising Overview - The company completed its initial public offering (IPO) of 64,249,446 shares at a price of 6.70 RMB per share, raising a total of 430,471,288.20 RMB, with a net amount of 384,363,201.32 RMB after deducting issuance costs [1][2]. - The funds have been stored in a dedicated account, and a tripartite supervision agreement has been signed with the sponsor and the bank [2][3]. Group 2: Investment Project Details - The company plans to invest the raised funds in specific projects, with a total investment amount of 31,145.75 million RMB [3][4]. - Adjustments to the investment structure and usage of excess funds have been approved by the shareholders' meeting [3][5]. Group 3: Use of Self-raised Funds - As of June 30, 2025, the company has utilized 8.7146 million RMB of self-raised funds for its projects, with an equivalent amount planned for replacement by the raised funds [5][6]. - The specific projects include medical imaging product development and industrial non-destructive testing system research [6]. Group 4: Approval Process - The board of directors and the supervisory board have approved the use of raised funds to replace self-raised funds, confirming compliance with legal regulations and ensuring no adverse effects on shareholder interests [7]. - The sponsor has verified that the replacement of funds does not alter the intended use of the raised funds or harm shareholder interests [7].